

**Date: 09 April 2025**

To

The Secretary <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 <b>Scrip Code: 544293</b>	The Secretary <b>The National Stock Exchange of India Limited</b> Exchange Plaza, Plot No. C/1. G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 <b>Scrip Symbol: SURAKSHA</b>
---	---

**Dear Sir / Ma'am,**

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update on acquisition**

**Ref: Our letters dated 27 March 2025 and 07 April 2025**

This is in furtherance to our earlier communications referenced above, wherein we had informed the exchanges about the strategic investment by Suraksha Diagnostic Limited ('the Company') in Fetomat Wellness Private Limited ('Fetomat') for an amount not exceeding ₹5.19 crores, in cash, in one or more tranches ('Acquisition').

We wish to inform you that the Company has today completed the said acquisition and as on the date of this letter, the Company holds 63% equity stake in Fetomat, thereby making Fetomat a subsidiary of the Company.

The other details of the acquisition, as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024, were disclosed in our letter dated 27 March 2025.

In compliance with Regulation 30(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this disclosure is also being made available on the Company's website at [www.surakshanet.com](http://www.surakshanet.com).

You are requested to kindly take the above on record.

**For Suraksha Diagnostic Limited**

\_\_\_\_\_  
Mamta Jain  
Company Secretary & Compliance Officer